Xu Jinxin, Hong Zhinuan, Cai Yingjie, Chen Zhen, Lin Jingping, Yuan Xi, Chen Shuchen, Xie Jinbiao, Kang Mingqiang, Ke Sunkui
Department of Thoracic Surgery, Zhongshan Hospital Xiamen University, Xiamen, China.
Fujian Medical University, Fuzhou, China.
Front Oncol. 2024 Feb 15;14:1279733. doi: 10.3389/fonc.2024.1279733. eCollection 2024.
This study investigates the prognostic significance of inflammatory nutritional scores in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) undergoing neoadjuvant chemoimmunotherapy.
A total of 190 LA-ESCC patients were recruited from three medical centers across China. Pre-treatment laboratory tests were utilized to calculate inflammatory nutritional scores. LASSO regression and multivariate logistic regression analyses were conducted to pinpoint predictors of pathological response. Kaplan-Meier and Cox regression analyses were employed to assess disease-free survival (DFS) prognostic factors.
The cohort comprised 154 males (81.05%) and 36 females (18.95%), with a median age of 61.4 years. Pathological complete response (pCR) was achieved in 17.38% of patients, while 44.78% attained major pathological response (MPR). LASSO and multivariate logistic regression analyses identified that hemoglobin, albumin, lymphocyte, and platelet (HALP) (P=0.02) as an independent predictors of MPR in LA-ESCC patients receiving neoadjuvant chemoimmunotherapy. Kaplan-Meier and log-rank tests indicated that patients with low HALP, MPR, ypT1-2, ypN0 and, ypTNM I stages had prolonged DFS (P < 0.05). Furthermore, univariate and multivariate Cox regression analyses underscored HALP (P = 0.019) and ypT (P = 0.029) as independent predictive factors for DFS in ESCC.
Our study suggests that LA-ESCC patients with lower pre-treatment HALP scores exhibit improved pathological response and reduced recurrence rate. As a comprehensive index of inflammatory nutritional status, pre-treatment HALP may be a reliable prognostic marker in ESCC patients undergoing neoadjuvant chemoimmunotherapy.
本研究探讨炎症营养评分在接受新辅助化疗免疫治疗的局部晚期食管鳞状细胞癌(LA-ESCC)患者中的预后意义。
从中国三个医疗中心招募了总共190例LA-ESCC患者。利用治疗前实验室检查来计算炎症营养评分。进行LASSO回归和多因素逻辑回归分析以确定病理反应的预测因素。采用Kaplan-Meier法和Cox回归分析来评估无病生存(DFS)的预后因素。
该队列包括154名男性(81.05%)和36名女性(18.95%),中位年龄为61.4岁。17.38%的患者实现了病理完全缓解(pCR),而44.78%的患者达到了主要病理缓解(MPR)。LASSO和多因素逻辑回归分析确定血红蛋白、白蛋白、淋巴细胞和血小板(HALP)(P=0.02)是接受新辅助化疗免疫治疗的LA-ESCC患者MPR的独立预测因素。Kaplan-Meier法和对数秩检验表明,HALP低、MPR、ypT1-2、ypN0和ypTNM I期的患者DFS延长(P<0.05)。此外,单因素和多因素Cox回归分析强调HALP(P=0.019)和ypT(P=0.029)是ESCC患者DFS的独立预测因素。
我们的研究表明,治疗前HALP评分较低的LA-ESCC患者表现出更好的病理反应和更低的复发率。作为炎症营养状态的综合指标,治疗前HALP可能是接受新辅助化疗免疫治疗的ESCC患者的可靠预后标志物。